SCHEMBL742297

SCHEMBL742297

NCCCCN(CCCN)CCCN

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.50
NFKB1 P19838 1/20 0.50
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA3 P07451 2/20 0.47
CA4 P22748 2/20 0.47
CA6 P23280 2/20 0.47
CA5A P35218 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
DNM1 Q05193 2/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
BLM P54132 1/20 0.47
LCK P06239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29225342 1.00 CHRM2 (0.50) CHRM2NFKB1CA12CA1CA2
SCHEMBL817873 0.97 CHRM2 (0.55) CHRM2NFKB1CA12CA1CA2
SCHEMBL16492062 0.97 CHRM2 (0.48) CHRM2NFKB1CA12CA1CA2
Hydrochloric Acid SCHEMBL19555655 0.97 CHRM2 (0.48) CHRM2NFKB1CA12CA1CA2
SCHEMBL560600 0.97 CHRM2 (0.55) CHRM2NFKB1CA12CA1CA2
SCHEMBL63987 0.96 NFKB1 (0.54) CHRM2NFKB1CA12CA1CA2
SCHEMBL636385 0.96 CHRM2 (0.45) CHRM2NFKB1CA12CA1CA2
SCHEMBL10972803 0.94 LCK (0.48) CHRM2NFKB1CA12CA1CA2
SCHEMBL2402964 0.93 CHRM2 (0.50) CHRM2NFKB1CA12CA1CA2
SCHEMBL720253 0.93 CHRM2 (0.58) CHRM2NFKB1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025047826-A1 CHROMATOGRAPHY CARRIER AND METHOD FOR PURIFYING ANTIBODY JNC株式会社 2025-03-06 WO claimed
EP-3894477-B1 CONTROLLED CURE FOR COMPOSITIONS COMPRISING ACETOACETYLATED RESINS EASTMAN CHEM CO (US) 2025-01-15 EP claimed
EP-3894475-B1 ASSEMBLY COMPONENTS COMPRISING CURABLE COMPOSITIONS CONTAINING ACETOACETYLATED RESINS EASTMAN CHEM CO (US) 2024-06-19 EP claimed
US-11820923-B2 Controlled cure for compositions comprising acetoacetylated resins EASTMAN CHEMICAL COMPANY (US) 2023-11-21 US claimed
EP-3894474-B1 CURABLE COMPOSITIONS COMPRISING ACETOACETYLATED RESINS, ALDEHYDES AND CERTAIN AMINES EASTMAN CHEM CO (US) 2023-09-13 EP claimed
US-11530342-B2 Curable compositions comprising acetoacetylated resins, aldehydes and certain amines EASTMAN CHEMICAL COMPANY (US) 2022-12-20 US claimed
US-11434400-B2 Assembly components comprising curable compositions containing acetoacetylated resins EASTMAN CHEMICAL COMPANY (US) 2022-09-06 US claimed
US-11261359-B2 Flexible substrates comprising curable compositions containing acetoacetylated resins EASTMAN CHEMICAL COMPANY (US) 2022-03-01 US claimed
EP-3894476-A1 FLEXIBLE SUBSTRATES COMPRISING CURABLE COMPOSITIONS CONTAINING ACETOACETYLATED RESINS Eastman Chemical Company (US) 2021-10-20 EP claimed
EP-3894475-A1 ASSEMBLY COMPONENTS COMPRISING CURABLE COMPOSITIONS CONTAINING ACETOACETYLATED RESINS Eastman Chemical Company (US) 2021-10-20 EP claimed
US-20180133664-A1 Methods for Treating Filled Microporous Membranes PPG INDUSTRIES OHIO, INC. 2018-05-17 US claimed
CN-102666667-B Functionalized highly branched melamine-polyamine polymers BASF SE 2015-03-04 CN claimed
EP-2513201-A1 FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS BASF SE (DE) 2012-10-24 EP claimed
US-20120252987-A1 FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS BASF SE (DE) 2012-10-04 US claimed
WO-2011073246-A1 FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS BASF SE (DE) 2011-06-23 WO claimed
EP-1778713-B1 METHOD FOR LABELLING AND PURIFYING NUCLEIC ACIDS OF INTEREST PRESENT IN A BIOLOGICAL SAMPLE TO BE TREATED IN A SINGLE REACTION VESSEL BIOMERIEUX SA (FR) 2008-12-31 EP claimed
JP-2007530024-A 2007-11-01 JP claimed
EP-1727825-A1 LABELLING REAGENTS, METHODS FOR THE SYNTHESIS OF SUCH REAGENTS AND METHODS FOR THE DETECTION OF BIOLOGICAL MOLECULES BIOMERIEUX (FR) 2006-12-06 EP claimed
WO-2005092910-A1 LABELLING REAGENTS, METHODS FOR THE SYNTHESIS OF SUCH REAGENTS AND METHODS FOR THE DETECTION OF BIOLOGICAL MOLECULES BIOMERIEUX (FR) 2005-10-06 WO claimed
US-6545067-B1 Polycarboxylate-based plasticizer and, as an air detrainer, butoxylated polyalkylenepolyamines or salts thereof mixed with a mineral building material comprising cement. BASF AKTIENGESELLSCHAFT (DE) 2003-04-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252987-A1 FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS PARN, INMT, SRM CHRM2 1253/4885NFKB1 3129/4885CA12 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.